Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Looks Health Services Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹8.61 |
|---|---|
| Day's Range | ₹8.56 - ₹8.65 |
| Open | ₹8.65 |
| 52 Week Range | ₹03.57 - ₹10.94 |
| Volume | 2,753 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 0.24 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 398.54 |
| TTM EPS (₹) | 0.02 |
| P/E Ratio | 203.51 |
| Book Value(₹) | 0.62 |
| PAT Margin (%) | 6.06 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 0.37 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 0.7 | 3.95 |
| Expenses | N/A | N/A |
| PBT | 0.02 | 0.29 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 0.02 | 0.24 |
About Looks Health Services Ltd.
| Founded | 2011 |
|---|
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,56,113.58 | 1,900.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,27,957.87 | 8,550.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,89,989.94 | 4,880.50 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,25,380.22 | 8,659.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,141.01 | 1,426.20 | 1,165.70 - 1,165.70 |
| Lenskart Solutions Ltd. | 1,13,820.20 | 661.55 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,10,603.22 | 1,120.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,00,733.42 | 2,193.00 | 1,875.00 - 1,875.00 |
| Dr. Reddy's Laboratories Ltd. | 98,604.43 | 1,175.00 | 1,101.00 - 1,101.00 |
| Mankind Pharma Ltd. | 98,499.54 | 2,372.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Looks Health Services informs about outcome of board meeting
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Looks Health Services has informed that the Board of Directors of the Company in its meeting held today on Tuesday, 4th August, 2026 at the Registered Office of the Company has considered and approved following businesses: Un‐audited Financial Results and Limited Review Report (issued by KPSJ Associates & LLP, Statutory Auditors) for the quarter ended 30th June, 2026 is enclosed. Further, as per the Company's Code of Conduct for Prohibition of Insider Trading, the Trading Window is already closed from 01st July, 2026 and will remain close till completion of 48 hours of declaration of the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026, on such information being made public for all Directors, KMPs Designated Employees and Connected Persons of the Company as defined in the Code. The board meeting commenced at 02:45 PM and concluded at 03:15 PM.
Indoco Remedies submits notice of 79th AGM
Aster DM Quality Care informs about SAST
Concord Biotech informs about analyst meet
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, Concord Biotech has informed that the officials of the Company will be attending an Investor Conference on 26th August 2026 at 01:00 PM to 03:00 PM (IST) organised by Phillip Capital PCG in Ahmedabad. Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) SingleDose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. Glenmark’s Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA, LLC [NDA 208418].
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Looks Health Services Ltd. is ₹8.61 as of 2026-08-21.
The market capitalisation of Looks Health Services Ltd. is ₹9.17 as of 2026-08-20.
The 1-year return of Looks Health Services Ltd. is 1.88% as of 2025-08-18.
The P/E ratio of Looks Health Services Ltd. is 203.51 as of 2026-08-21.
The 52-week high and low of Looks Health Services Ltd. are ₹10.94 and ₹3.57, respectively, as of 2026-08-21.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
